semaglutide short term Two-year effects of in adults with overweight or obesity: the STEP 5 trial Video Patel it Like it

Consuming smaller portions more often can help manage feelings of fullness and reduce nausea

Patients can view current Wegovy availability (official Ro page) to confirm terms before discussing options with a licensed clinician

Bottom line (short) Tirzepatide is a novel dual GIP/GLP-1 receptor agonist that produces substantially greater average weight loss (in SURMOUNT-1 up to ~21% with 15 mg at 72 weeks) than placebo and larger weight and A1c reductions than some comparator GLP-1 therapies in trials

Kato S, Sato T, Fujita H, Kawatani M, Yamada Y

K., Bienenstock, J

Regular monitoring of inflammatory markers, disease activity scores, and functional status remains essential regardless of concurrent GLP-1 use